MA53322A - Anticorps procoagulants améliorés - Google Patents

Anticorps procoagulants améliorés

Info

Publication number
MA53322A
MA53322A MA053322A MA53322A MA53322A MA 53322 A MA53322 A MA 53322A MA 053322 A MA053322 A MA 053322A MA 53322 A MA53322 A MA 53322A MA 53322 A MA53322 A MA 53322A
Authority
MA
Morocco
Prior art keywords
procoagulant antibodies
enhanced procoagulant
enhanced
antibodies
procoagulant
Prior art date
Application number
MA053322A
Other languages
English (en)
Inventor
Jianhe Chen
Per J Greisen
Bjarne Gram Hansen
Mikkel Nors Harndahl
Eva Johansson
Laust Bruun Johnsen
Morten Grønbech Rasch
Anders Svensson
Karina Thorn
Zhiru Yang
Rong Zhou
Haisun Zhu
Henrik Østergaard
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA53322A publication Critical patent/MA53322A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA053322A 2018-08-01 2019-07-31 Anticorps procoagulants améliorés MA53322A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018097834 2018-08-01
CN2018099339 2018-08-08
EP18193191 2018-09-07

Publications (1)

Publication Number Publication Date
MA53322A true MA53322A (fr) 2021-11-10

Family

ID=67480228

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053322A MA53322A (fr) 2018-08-01 2019-07-31 Anticorps procoagulants améliorés

Country Status (18)

Country Link
US (1) US20230058721A1 (fr)
EP (1) EP3830135A1 (fr)
JP (3) JP6761142B1 (fr)
KR (2) KR102382743B1 (fr)
CN (3) CN112513096B (fr)
AU (1) AU2019313550B2 (fr)
CA (1) CA3113797A1 (fr)
CL (2) CL2021000186A1 (fr)
CO (1) CO2021001046A2 (fr)
IL (1) IL280239B2 (fr)
MA (1) MA53322A (fr)
MX (1) MX2021001064A (fr)
MY (1) MY202203A (fr)
PE (1) PE20211399A1 (fr)
PH (1) PH12021550117A1 (fr)
SG (1) SG11202100418PA (fr)
TW (1) TWI716059B (fr)
WO (1) WO2020025672A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250376538A1 (en) * 2020-01-30 2025-12-11 Novo Nordisk A/S Bispecific factor viii mimetic antibodies
KR102868672B1 (ko) 2022-03-02 2025-10-14 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Fviii 모방 이중특이적 항체를 2주마다 1회 투여하는 방법
CN118786149A (zh) * 2022-03-02 2024-10-15 诺和诺德医疗保健公司 每两周施用fviii模拟双特异性抗体的方法
KR102839278B1 (ko) * 2022-03-02 2025-07-30 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Fviii 모방 이중특이적 항체의 월 1회 투여 방법
KR102839225B1 (ko) 2022-03-02 2025-07-29 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Fviii 모방 이중특이적 항체의 주 1회 투여 방법
US12098400B2 (en) 2022-07-08 2024-09-24 Novo Nordisk A/S Highly potent ISVD compounds capable of substituting for FVIII(A)
IL317317A (en) 2022-07-08 2025-01-01 Novo Nordisk As Highly potent ISVD compounds capable of replacing FVIII(A)
TW202500585A (zh) * 2023-06-23 2025-01-01 瑞士商諾佛 儂迪克保健股份公司 每兩個月投予一次fviii模擬雙特異性抗體之方法
GB202408056D0 (en) * 2024-06-06 2024-07-24 Cambridge Entpr Ltd Anticoagulant protein molecules and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
ATE299938T1 (de) * 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US7297336B2 (en) * 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
WO2005035753A1 (fr) * 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Anticorps a double specificite remplaçant une proteine fonctionnelle
AU2003271186A1 (en) * 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
PT1876236E (pt) * 2005-04-08 2014-10-22 Chugai Pharmaceutical Co Ltd Anticorpos para substituição da função do factor de coagulação sanguínea viii
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
EP2847228B1 (fr) * 2012-05-10 2018-07-25 Bayer Pharma Aktiengesellschaft Anticorps capables de lier au facteur de coagulation xi et/ou à sa forme activée, le facteur xia, et utilisations de ceux-ci
WO2015067755A2 (fr) * 2013-11-07 2015-05-14 Novo Nordisk A/S Nouvelles méthodes et nouveaux anticorps destinés au traitement d'une coagulopathie
TWI700300B (zh) * 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
JP6698102B2 (ja) * 2015-04-17 2020-05-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 凝固因子と多重特異的抗体を用いた併用療法
TN2019000164A1 (en) * 2016-11-23 2020-10-05 Bioverativ Therapeutics Inc Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x
EP3577140A1 (fr) 2017-02-01 2019-12-11 Novo Nordisk A/S Anticorps procoagulants
US11220554B2 (en) * 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies

Also Published As

Publication number Publication date
JP2020115863A (ja) 2020-08-06
CL2025001281A1 (es) 2025-08-22
MX2021001064A (es) 2021-04-12
TW202007696A (zh) 2020-02-16
US20230058721A1 (en) 2023-02-23
CN112513096B (zh) 2023-08-25
SG11202100418PA (en) 2021-02-25
PH12021550117A1 (en) 2021-10-04
KR20210040389A (ko) 2021-04-13
WO2020025672A9 (fr) 2020-04-23
CN112513096A (zh) 2021-03-16
IL280239A (en) 2021-03-25
JP6761142B1 (ja) 2020-09-23
WO2020025672A1 (fr) 2020-02-06
CO2021001046A2 (es) 2021-04-30
KR102382743B1 (ko) 2022-04-12
PE20211399A1 (es) 2021-07-27
BR112021000823A2 (pt) 2021-04-13
JP7094314B2 (ja) 2022-07-01
AU2019313550A1 (en) 2021-02-04
KR20210091839A (ko) 2021-07-22
TWI716059B (zh) 2021-01-11
AU2019313550B2 (en) 2024-02-08
CL2021000186A1 (es) 2021-07-02
JP2020530449A (ja) 2020-10-22
CA3113797A1 (fr) 2020-02-06
JP7355874B2 (ja) 2023-10-03
JP2022084858A (ja) 2022-06-07
CN117384296A (zh) 2024-01-12
MY202203A (en) 2024-04-17
IL280239B2 (en) 2026-03-01
IL280239B1 (en) 2025-11-01
KR102887629B1 (ko) 2025-11-19
CN117343188A (zh) 2024-01-05
EP3830135A1 (fr) 2021-06-09

Similar Documents

Publication Publication Date Title
MA52884A (fr) Anticorps anti-il-11
MA53434A (fr) Anticorps anti-tigit
EP3903817A4 (fr) Nouvel anticorps anti-ccr8
MA53322A (fr) Anticorps procoagulants améliorés
EP3784699A4 (fr) Anticorps anti-tl1a optimisés
EP3883970A4 (fr) Anticorps anti-b7-h3
MA49034A (fr) Anticorps anti-lag3
EP3589313A4 (fr) Anticorps anti-tigit
MA47268A (fr) Anticorps anti-gpc3
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA44659A (fr) Anticorps anti-tim-3 et compositions
EP3498840A4 (fr) Anticorps anti-lag-3
EP3442579A4 (fr) Anticorps anti-vista humain et utilisation associée
EP3423089A4 (fr) Anticorps anti-tigit
EP3684806A4 (fr) Nouveaux anticorps anti-cd3epsilon
MA44236A (fr) Anticorps anti-tgfbêta 2
EP3492591A4 (fr) Anticorps anti-b7-h4
MA52152A (fr) Anticorps
EP3617231A4 (fr) Anticorps anti-gpc-1
EP3526247A4 (fr) Anticorps anti-il1-rap
MA51134A (fr) Anticorps anti-alpha-synucléine
EP3831851A4 (fr) Anticorps anti-btla
EP3596126A4 (fr) Nouveaux anticorps anti-trkb
EP3484919A4 (fr) Anticorps anti-bêta-amyloïde
EP3399992A4 (fr) Anticorps autoréticulants